January 2025 Br J Cardiol 2025;32:31–5 doi:10.5837/bjc.2025.003
Elliott J Carande, Keiron Morgan, Chayanee Leenachunangkool, Joy Shome, Ahmed Hailan, Ayush Khurana, Dave Smith, Alexander Chase, Daniel R Obaid
Abstract
Introduction
Aortic stenosis (AS) is a common valvular pathology that becomes more common with age, with recent studies suggesting a prevalence of approximately 10% in octogenarians.1,2 Current guidelines recommend valvular intervention in severe AS in those patients who are symptomatic.3 Management of AS has been revolutionised by the advent of transcatheter aortic valve implantation (TAVI), initially for those patients deemed too high risk to undergo a traditional surgical aortic valve replacement (SAVR).4 More recently, transfemoral TAVI is now the treatment of choice in patients >75 years of age, irrespective of surgical risk, or in yo
|
Full text
